Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester.
Ellen S
ES
Bruce
Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester.
Lianne
L
Kearsley-Fleet
Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester.
Kath D
KD
Watson
Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, Manchester, UK.
Deborah P M
DP
Symmons
Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, Manchester, UK kimme.hyrich@manchester.ac.uk.
Kimme L
KL
Hyrich
D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001688:Biological Products / Q000009:adverse effects*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000276:immunology*; D011020:Pneumonia, Pneumocystis / Q000276:immunology*; D012042:Registries; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D001688:Biological Products; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha